Company news
Madrigal Pharmaceuticals, Inc. news in 2020
Madrigal Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
November 4, 2020
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
September 2, 2020
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
August 25, 2020
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
August 5, 2020
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights
May 6, 2020
Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction
April 13, 2020
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
February 25, 2020
Decks in 2020
- AASLD 2020
Conference · 41 slides · November 2020